Acute cytolitic hepatitis associated with venlafaxine treatment [7];Hépatite aiguë cytolytique après prise de venlafaxine [7]

Gastroenterologie Clinique et Biologique

Volumn 26, Issue 8-9, 2002, Pages 804-

  Maroy, Bernard ^a  

^a Maison Medicale de Lunesse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDEPRESSANT AGENT; ASPARTATE AMINOTRANSFERASE; LORMETAZEPAM; PHENETHYLAMINE DERIVATIVE; TRAZODONE; VENLAFAXINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DEPRESSION; HEPATITIS; HUMAN; LETTER; LIVER TOXICITY; MALE; SYMPTOMATOLOGY;

ACUTE DISEASE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHOLESTASIS; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG ERUPTIONS; HEPATITIS, TOXIC; HUMANS; MALE; MIDDLE AGED;

EID: 0036698305     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Horsmans Y, de Clercq M, Sempoux C. Venlafaxine-associated hepatitis. Ann Intern Med 1999;130:944.
2. Kim KY, Hwang Ba W, Narendran R. Acute liver damage possibly related to sertraline and venlafaxine ingection. Ann Pharmacol 1999;33:381-2.
3. Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis. Ann Intern Med 2000;132:417.
4. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Therapie 1985;40:111-8.
5. Larrey D. Hépatites aiguës médicamenteuses. Imputabilité et aspects cliniques. Gastroenterol Clin Biol 1995;19:B57-62.